Boston Therapeutics Initiates New Exploratory and Adaptive Multicenter Clinical Study of BTI320 On Type 2 Diabetics Currently on Metformin and or Sulfonylureas in the United States

Boston Therapeutics announces the start of a new double-blind, placebo-controlled study that will confirm the potential of the newly patented (EU) investigative material to support and possibly enhance current anti-diabetic regimen of glycemic control in https://markets.businessinsider.com/news/stocks/boston-therapeutics-initiates-new-exploratory-and-adaptive-multicenter-clinical-study-of-bti320-on-type-2-diabetics-currently-on-metformin-and-or-sulfonylureas-in-the-united-states-1027559492